Atypical progression of multiple myeloma with extensive extramedullary disease.

J Clin Pathol

Department of Haematology, Bradford Royal Infirmary, West Yorkshire.

Published: March 1994

Multiple myeloma is a neoplastic disorder caused by the proliferation of a transformed B lymphoid progenitor cell that gives rise to a clone of immunoglobulin-secreting cells. Other plasma cell tumours include solitary plasmacytoma of bone (SPB) and extramedullary plasmacytomas (EMP). Despite an apparent common origin there exist pathological and clinical differences between these neoplasms and the association between them is not completely understood. A case of IgG multiple myeloma that presented with typical clinical and laboratory features, including a bone marrow infiltrated by well differentiated plasma cells, is reported. The tumour had an unusual evolution, with the development of extensive extramedullary disease while maintaining mature histological features.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC501910PMC
http://dx.doi.org/10.1136/jcp.47.3.269DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
12
extensive extramedullary
8
extramedullary disease
8
atypical progression
4
progression multiple
4
myeloma extensive
4
disease multiple
4
myeloma neoplastic
4
neoplastic disorder
4
disorder caused
4

Similar Publications

Introduction: CD20+ T-cells were described firstly in peripheral blood and later in bone marrow in patients with hematological tumors, and certain immune-mediated diseases. During our hematological diagnostic work, this peculiar subgroup of lymphocytes has been consistently observed associated with untreated monoclonal gammopathy of undetermined significance (MGUS) and myeloma (MM). Despite the expanding literature data, the exact function of CD20+ T cells remains unclear.

View Article and Find Full Text PDF

Multiple myeloma (MM) is a malignant disease of plasma cells that accounts for approximately 10% of all hematological malignancies and is characterized by a clonal proliferation of malignant plasma cells in the bone marrow. Numerous therapeutic strategies, including proteasome inhibitors, immunomodulators, monoclonal antibodies against CD38 and autologous stem cell transplantation, have prolonged the median survival of MM patients. Nevertheless, almost all MM patients suffer disease relapses due to drug resistance and eventually die from MM or MM-related complications.

View Article and Find Full Text PDF

Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cells (CAR-T) have been used as consolidation therapies for patients with refractory/relapsed B cell non-Hodgkin's lymphoma (R/R B-NHL) in remission after second-line chemotherapy or salvage therapy. However, patients with different pathological subtypes and remission states may benefit differently from ASCT or CAR-T cell therapy. Furthermore, consolidation treatment involving ASCT or CAR-T cells still poses a significant risk of disease relapse.

View Article and Find Full Text PDF

Mapping the landscape of vitamin D in cancer studies: a systematic global investigation.

J Diabetes Metab Disord

June 2025

Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular - Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Purpose: This comprehensive study examines the multifaceted relationship between vitamin D and cancer, synthesizing key scientific advancements and global research trends to guide future investigations and address critical gaps in the field.

Methods: Publications on vitamin D and cancer were retrieved from Scopus up to November 2024. English-language original and review articles were analyzed using Excel, VOSviewer, and Scimago Graphica, focusing on publication trends, citation impacts, and research themes.

View Article and Find Full Text PDF

Objectives: Multiple myeloma (MM) is an incurable hematological malignancy, Dual-specificity phosphatase-1 (DUSP1) plays a crucial role in the initiation and progression of various tumors. Here, we aim to elucidate the role of DUSP1 in MM.

Methods: DUSP1 mRNA expression was analyzed based on public datasets, and protein expression was determined by immunohistochemistry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!